Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment

Haematologica

Volumn 95, Issue 2, 2010, Pages 339-340

  Remacha, Angel F ^a   Arrizabalaga, Beatriz ^a   Bueno, Javier ^a   Muñoz, Juan ^a   Bargay, Joan ^a   Pedro, Carme ^a  

^a NONE

Author keywords

Erythropoietin; Immunosuppression; Mycophenolate; Myelodysplastic syndrome

Indexed keywords

CELL CEPT; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

BLOOD TRANSFUSION; DIARRHEA; DRUG DOSE INCREASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; PNEUMONIA; TREATMENT RESPONSE;

DRUG RESISTANCE; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID; MYELODYSPLASTIC SYNDROMES;

EID: 76549114236     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.016956     Document Type: Letter

References (11)

1. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89(12): 4248-67.
2. Malcovati L, Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30): 7594-603.
3. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, et al; Scandinavian MDS Group. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. 2003;120(6):1037-46.
4. Remacha AF, Arrizabalaga B, Villegas A, Manteiga R, Calvo T, Julia A, Fernandez Fuertes I, Gonzalez FA, Font L, Junca J, del Arco A, Malcorra JJ, Equiza EP, de Mendiguren BP, Romero M. Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodysplastic syndromes. Identification of a subgroup of responders. Haematologica. 1999;84(12):1058-64.
5. Jadersten M, Montgomery SM, Dybedal I, Porwit-MacDonald A, Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005;106(3):803-11.
6. Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophisiology of myelodysplastic syndromes and their clinical relevance. Haematologica. 2009;94(4):449-51.
7. Shimamoto T, Ohyashiki K. Immunosuppressive treatments for myelodysplastic syndromes. Leuk Lymphoma. 2003;44(4):593-604.
8. Sloand EM, Mainwaring L, Fuhrer M, Ramkissoon S, Risitano AM, Keyvanafar K, et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood. 2005;106(3):841-51.
9. Steensma DP, Dispenzieri A, Moore SB, Schroeder G, Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003;101(6):2156-8.
10. Kotb R, Pinganaud C, Trichet C, Lambotte O, Dreyfus M, Delfraissy JF, et al. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study. Eur J Haematol 2005;75(1):60-4.
11. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, et al; World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96(12):3671-4.